Fig. 3
From: NKX2–1 expression as a prognostic marker in early-stage non-small-cell lung cancer
Kaplan Meier analysis of overall survival according to NKX2–1 expression levels in patients harboring neither TP53 nor KRAS mutations in a the entire cohort and b patients with stage I disease